Argenx
ARGX
$949.24
Share price
-0.62%
Change (1 day)
63.37%
Change (1 year)
Categories
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.
Revenue for Argenx (ARGX)
Revenue in 2024 (TTM): A$3.34 Billion
According to Argenx
's latest financial reports the company's current revenue (TTM 
) is A$3.45 Billion. an increase over the revenue in the year 2023 that were of A$1.79 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Argenx from 2013 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | A$3.52 B | 95.63% |
| 2023 | A$1.79 B | 198.21% |
| 2022 | A$0.60 B | |
| 2019 | A$0.12 B | 202.72% |
| 2018 | A$41.35 M | -35.76% |
| 2017 | A$64.36 M | 171.38% |
| 2016 | A$23.71 M | 107.87% |
| 2015 | A$11.41 M | 61.52% |
| 2014 | A$7.06 M | 27.18% |
| 2013 | A$5.55 M |